PLYMOUTH MEETING, Pa., May 5, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea, Ph.D., President and CEO, will present at the 2023 RBC Capital Markets Global Healthcare Conference.
2023 RBC Capital Markets Global Healthcare Conference
Date: Wednesday, May 17, 2023
Time: 4:05 PM ET
Format: Fireside Chat
During the conference, Dr. Shea and members of INOVIO's management team will conduct one-on-one meetings with registered investors.
A webcast of the presentation will be available on the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx. A replay of the webcast will be available for 90 days after the date of the presentation.
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's DNA medicines in development are delivered using its investigational proprietary smart device, CELLECTRA®, to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.
Media: Jennie Willson (267) 429-8567 This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors: Thomas Hong (267) 440-4298 This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.00 |
Daily Change: | -0.04 -1.96 |
Daily Volume: | 531,906 |
Market Cap: | US$72.200M |
December 12, 2024 November 14, 2024 November 06, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load